Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as thre
Ionis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call Transcript
04:10pm, Wednesday, 19'th Feb 2025
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q4 2024 Earnings Conference Call February 19, 2025 11:30 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Ch
Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval
02:40pm, Wednesday, 19'th Feb 2025
Ionis Pharmaceuticals' Q4 earnings beat expectations, but guidance for 2025 was slightly below consensus, leading to a HOLD rating pending further catalysts. TRYNGOLZA's approval for FCS is promising,
Ionis Pharma Beats Expectations for Q4
01:26pm, Wednesday, 19'th Feb 2025
Ionis Pharmaceuticals (IONS 0.44%), a leader in RNA-targeted drug discovery and development, announced its earnings results for the fourth quarter on Feb. 19. The report revealed that Ionis outperform
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales
12:11pm, Wednesday, 19'th Feb 2025
On Wednesday, Ionis Pharmaceuticals Inc IONS reported a fourth-quarter EPS loss of $0.66, up from a loss of $0.06, beating the consensus of a $1.10 loss.
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say
10:35am, Wednesday, 19'th Feb 2025
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
09:10am, Wednesday, 19'th Feb 2025
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $0.06 per share a year ago.
Ionis reports fourth quarter and full year 2024 financial results
07:00am, Wednesday, 19'th Feb 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2024. “With
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS
10:21am, Monday, 17'th Feb 2025
Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of i
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
11:06am, Wednesday, 12'th Feb 2025
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis to hold fourth quarter and full year 2024 financial results webcast
07:05am, Wednesday, 05'th Feb 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19th at 11:30 a.m. Eastern Time to discuss its fou
Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034
09:17am, Wednesday, 15'th Jan 2025
The market will grow as a result of the increasing incidence of amyloidosis, technological advancements in diagnostics, increased focus on rare diseases, improved healthcare infrastructure, increased
– Accelerating value creation with numerous commercial, regulatory and pipeline milestones – – Ionis outlines clear path to sustained positive cash flow – CARLSBAD, Calif. , Jan. 13, 2025 /PRN
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
04:11pm, Wednesday, 08'th Jan 2025
CARLSBAD, Calif. , Jan. 8, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P.
Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval
07:30am, Monday, 23'rd Dec 2024
Ionis Pharmaceuticals applies proprietary antisense technology to tackle diseases at their genetic source, focusing on conditions such as FCS, Angelman syndrome, and HAE. The FDA approval of Tryngolza
